Farmak, the leader of the domestic pharmaceutical market, participated in the International Pharmaceutical Exhibition CPhI South East Asia 2015, held in Jakarta, Indonesia.
CPhI South East Asia 2015 in North Asia is one of the world's largest pharmaceutical forums. It is here that manufacturers of active pharmaceutical ingredients, and pharmaceutical, laboratory and analytical equipment, and packaging technologies represent their products. Overall, CPhI South East Asia 2015 hosted 260 companies. The exhibition was attended by more than 5,500 experts from around the world.
It is worth mentioning that Indonesia is a member of the Association of Southeast Asian Nations (ASEAN), which also includes South Korea, Taiwan, Singapore, Thailand, Philippines, Malaysia, and Vietnam. Overall, the region is classified as that having significant economic growth potential of Indonesia, Thailand and the Philippines due to large populations and constantly growing economy, accompanied by increase of salaries and healthcare system priority for regional governments.
Oleg Syarkevych, Business Development Director, Farmak, says, “The ASEAN region is currently deploying several initiatives to develop the pharmaceutical industry. These include new priority regulatory measures with the assistance and consent of the ASEAN Economic Community and the introduction of universal health protection schemes, particularly in Indonesia, which is on the way to the world’s largest healthcare system planned to be implemented by 2019.
The Company’s participation in the CPhI opens the gate to this market and enables direct access to key decision-makers and distributors in the ASEAN's pharmaceutical market, one of Farmak's strategic directions to expand export markets”.
The pharmaceutical company JSC “Farmak” considers the possibility of launching the manufacture of products, in particular, diagnostic test kits, to combat coronavirus spread. “Now we analyse the possibility of arranging the release of supportive care products, disinfectants and antiseptics, diagnostic test kits, protective medical products, including masks, ...
Farmak reinvests 95% of its profits in the development. “We have never paid more than 5% of our profits as dividends. We have reinvested everything in the development. Due to this, Farmak’s capitalization can be estimated at $850 million to $1 billion today. If I sell the shares that I hold, I will earn a […]
The Memorandum is aimed at developing the mutual cooperation in the implementation of the state programs of the Republic of Uzbekistan for the further development of the national pharmaceutical industry. “We know the Uzbek market well and we are committed to develop cooperation. Farmak has been present in Uzbekistan since 2004. The residents of this [&hellip...